Three-year outcomes of vitrectomy combined with intraoperative dexamethasone implantation for non-tractional refractory diabetic macular edema

Three-year outcomes of vitrectomy combined with intraoperative dexamethasone implantation for non-tractional refractory diabetic macular edema

1.Yau, J. W. et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35, 556–564 (2012).Article 

Google Scholar 
2.Daruich, A. et al. Mechanisms of macular edema: Beyond the surface. Prog. Retin. Eye Res. 63, 20–68 (2018).Article 

Google Scholar 
3.Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 103, 1796–1806 (1985).4.Wells, J. A. et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 123, 1351–1359 (2016).Article 

Google Scholar 
5.Arevalo, J. F. et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: The Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 116, 1488–1497, 1497 e1481 (2009).6.Gillies, M. C. et al. Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113, 1533–1538 (2006).Article 

Google Scholar 
7.Boyer, D. S. et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121, 1904–1914 (2014).Article 

Google Scholar 
8.Entezari, M. et al. Posterior sub-tenon triamcinolone for refractory diabetic macular edema: A randomized clinical trial. Eur. J. Ophthalmol. 15, 746–750 (2005).CAS 
Article 

Google Scholar 
9.Diabetic Retinopathy Clinical Research, N. et al. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: A pilot study. Ophthalmology 114, 1190–1196 (2007).10.Hartley, K. L., Smiddy, W. E., Flynn, H. W. Jr. & Murray, T. G. Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina 28, 410–419 (2008).Article 

Google Scholar 
11.Kumagai, K. et al. Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina 29, 464–472 (2009).Article 

Google Scholar 
12.Rosenblatt, B. J., Shah, G. K., Sharma, S. & Bakal, J. Pars plana vitrectomy with internal limiting membranectomy for refractory diabetic macular edema without a taut posterior hyaloid. Graefes Arch. Clin. Exp. Ophthalmol. 243, 20–25 (2005).Article 

Google Scholar 
13.Lee, G. H., Ahn, J. K. & Park, Y. G. Intravitreal triamcinolone reduces the morphologic changes of ciliary body after pars plana vitrectomy for retinal vascular diseases. Am. J. Ophthalmol. 145, 1037–1044 (2008).CAS 
Article 

Google Scholar 
14.Chin, H. S., Park, T. S., Moon, Y. S. & Oh, J. H. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 25, 556–560 (2005).Article 

Google Scholar 
15.Chang-Lin, J. E. et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest. Ophthalmol. Vis. Sci. 52, 4605–4609 (2011).CAS 
Article 

Google Scholar 
16.Medeiros, M. D. et al. Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema. J. Ocul. Pharmacol. Ther. 30, 709–716 (2014).CAS 
Article 

Google Scholar 
17.Iglicki, M. et al. Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: The international retina group real-life 24-month multicenter study. The IRGREL-DEX Study. Retina 39, 44–51 (2019).CAS 
Article 

Google Scholar 
18.Mello Filho, P. et al. Effectiveness and safety of intravitreal dexamethasone implant (ozurdex) in patients with diabetic macular edema: A real-world experience. Ophthalmologica 241, 9–16 (2019).CAS 
Article 

Google Scholar 
19.Iglicki, M., Zur, D., Busch, C., Okada, M. & Loewenstein, A. Progression of diabetic retinopathy severity after treatment with dexamethasone implant: A 24-month cohort study the “DR-Pro-DEX Study”. Acta Diabetol. 55, 541–547 (2018).CAS 
Article 

Google Scholar 
20.Zur, D. et al. Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant. Acta Ophthalmol. 98, e217–e223 (2020).CAS 
Article 

Google Scholar 
21.Iglicki, M. et al. TRActional DIabetic reTInal detachment surgery with co-adjuvant intravitreal dexamethasONe implant: the TRADITION STUDY. Acta Diabetol. 56, 1141–1147 (2019).CAS 
Article 

Google Scholar 
22.Lee, D. H., Kim, Y. J. & Yoon, Y. H. Minimally invasive microincision vitrectomy surgery with an intraoperative dexamethasone implant for refractory diabetic macular edema. Ophthalmologica 235, 150–156 (2016).CAS 
Article 

Google Scholar 
23.Kim, K. T. et al. Vitrectomy combined with intraoperative dexamethasone implant for the management of refractory diabetic macular edema. Korean J. Ophthalmol. 33, 249–258 (2019).CAS 
Article 

Google Scholar 
24.Jung, Y. H. & Lee, Y. Efficacy of vitrectomy combined with an intraoperative dexamethasone implant in refractory diabetic macular edema. Acta Diabetol. 56, 691–696 (2019).CAS 
Article 

Google Scholar 
25.Iglicki, M. et al. Biomarkers and predictors for functional and anatomic outcomes for small gauge pars plana vitrectomy and peeling of the internal limiting membrane in naive diabetic macular edema: The VITAL study. PLoS ONE 13, e0200365 (2018).Article 

Google Scholar 
26.Diabetic Retinopathy Clinical Research Network Writing, C. et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 117, 1087–1093 e1083 (2010).27.Choi, M. Y., Jee, D. & Kwon, J. W. Characteristics of diabetic macular edema patients refractory to anti-VEGF treatments and a dexamethasone implant. PLoS ONE 14, e0222364 (2019).CAS 
Article 

Google Scholar 
28.Flaxel, C. J. et al. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: Diabetic retinopathy clinical research network. Retina 30, 1488–1495 (2010).Article 

Google Scholar 
29.Kim, Y. T., Kang, S. W., Kim, S. J., Kim, S. M. & Chung, S. E. Combination of vitrectomy, IVTA, and laser photocoagulation for diabetic macular edema unresponsive to prior treatments; 3-year results. Graefes Arch. Clin. Exp. Ophthalmol. 250, 679–684 (2012).Article 

Google Scholar 
30.Kim, J., Kang, S. W., Shin, D. H., Kim, S. J. & Cho, G. E. Macular ischemia and outcome of vitrectomy for diabetic macular edema. Jpn. J. Ophthalmol. 59, 295–304 (2015).Article 

Google Scholar 
31.Yanyali, A., Horozoglu, F., Celik, E. & Nohutcu, A. F. Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina 27, 557–566 (2007).Article 

Google Scholar 
32.Hu, X. Y., Liu, H., Wang, L. N., Ding, Y. Z. & Luan, J. Efficacy and safety of vitrectomy with internal limiting membrane peeling for diabetic macular edema: a Meta-analysis. Int. J. Ophthalmol. 11, 1848–1855 (2018).PubMed 
PubMed Central 

Google Scholar 
33.Stefansson, E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol. Scand. 79, 435–440 (2001).CAS 
Article 

Google Scholar 
34.Otani, T. & Kishi, S. A controlled study of vitrectomy for diabetic macular edema. Am. J. Ophthalmol. 134, 214–219 (2002).Article 

Google Scholar 
35.Antonetti, D. A., Wolpert, E. B., DeMaio, L., Harhaj, N. S. & Scaduto, R. C. Jr. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J. Neurochem. 80, 667–677 (2002).CAS 
Article 

Google Scholar 
36.Zur, D., Iglicki, M. & Loewenstein, A. The role of steroids in the management of diabetic macular edema. Ophthalmic Res. 62, 231–236 (2019).CAS 
Article 

Google Scholar 
37.Pang, J. P., Son, G., Yoon, Y. H., Kim, J. G. & Lee, J. Y. Combined vitrectomy with intravitreal dexamethasone implant for refractory macular edema secondary to diabetic retinopathy, retinal vein occlusion, and noninfectious posterior uveitis. Retina 40, 56–65 (2020).Article 

Google Scholar 
38.Chang-Lin, J. E. et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest. Ophthalmol. Vis. Sci. 52, 80–86 (2011).CAS 
Article 

Google Scholar 
39.Avery, R. L. & Gordon, G. M. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol. 134, 21–29 (2016).Article 

Google Scholar 
40.Thakur, A., Kadam, R. & Kompella, U. B. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol. 129, 914–920 (2011).Article 

Google Scholar 
41.Yang, Y., Bailey, C., Loewenstein, A. & Massin, P. Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations. Retina 35, 2440–2449 (2015).CAS 
Article 

Google Scholar 

Via Source link